STAT

JANUARY 2, 2024

AUSTIN, Texas — Eleven years ago, local officials promised voters in the most liberal county in Texas that if they supported tens of millions of dollars in new taxes, they’d deliver a win-win scenario: Austin would get a new medical school, and poor people navigating the health care system in a state with the country’s worst uninsured rate would get more health care services.

Medical Schools 359

Medical Schools Hospitals 359

BioPharma Dive

JANUARY 2, 2024

A non-addictive pain pill faces its definitive test, while study results in ALS, a rare heart disease and lung cancer could have far-reaching implications.

143

143

STAT

JANUARY 2, 2024

The  blue muffin challenge. Food sensitivity tests. Microbiome test kits. Self-help gastrointestinal health is all the rage. Rightly so: One in four Americans is affected by digestive disorders. And we’re all eating worse, sleeping less, and experiencing more stress , leaving our guts feeling twisted.

333

333

BioPharma Dive

JANUARY 2, 2024

Amgen had its bid for full approval of the cancer drug Lumakras turned back by the agency, which also issued complete response letters to Zealand Pharma and Merck & Co. in December.

117

117

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JANUARY 2, 2024

The first phone call came some time in late 1996. “Ed, I’d like to introduce myself. My name is Sid Wolfe of Public Citizen,” he said. “And I’ve got something for you.” He started out matter of fact, but spoke very quickly. To be honest, I can’t recall the subject anymore, but I do remember he peppered every sentence with lots of medical terminology.

326

326

The Pharmacist

JANUARY 2, 2024

The universities of Bath and Plymouth have teamed up to offer more pharmacist training places at an additional location, to combat workforce shortages that particularly affects the South West of England. From this September, pharmacy students will be able to undertake the University of Bath MPharm course at the University of Plymouth, as well as […] The post Universities join forces to tackle pharmacist shortage in South West England appeared first on The Pharmacist.

111

111

The Pharmacist

JANUARY 2, 2024

There is a continued need for Covid boosters, according to a Government study, which found they provide significant protection against death but this wanes after six months. Researchers from the UK Health Security Agency analysed data on more than 10.6 million cases of Covid-19 in adults that had been recorded by England’s laboratory reporting system […] The post Covid boosters needed as vaccine protection wanes after six months, finds UKHSA appeared first on The Pharmacist.

Vaccines 111

Vaccines 111

STAT

JANUARY 2, 2024

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. Power, politics, and care for the poor in Texas Local officials in Austin, Texas promised twelve years ago that if voters approved millions of dollars in new property taxes, it would be a win-win.

Medical Schools 272

Medical Schools Hospitals 272

pharmaphorum

JANUARY 2, 2024

Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine, its therapy for chronic obstructive pulmonary disease (COPD). The Anglo-US company has already tapped $50 million of the funding and can take another $100 million if an ongoing review of ensifentrine by the US FDA results in regulatory approval.

110

110

STAT

JANUARY 2, 2024

WASHINGTON — The Biden administration seemed to be giving pharmacies a win when they forced pharmacy benefit managers to be more up-front about the behind-the-scenes fees they charge. But now pharmacies are afraid the transition to the new system on Jan. 1 will lead to a cash flow crunch. In the past, PBMs could charge pharmacies performance-based fees long after the fact, and the total amount of the fees has grown in recent years.

267

267

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

PharmExec

JANUARY 2, 2024

Companies must address myriad challenges to improve upon issues such as data quality and transparency, process efficiency, and artificial intelligence/machine learning preparedness.

98

98

STAT

JANUARY 2, 2024

AUSTIN, Texas — The partnership between one of the nation’s largest Catholic health systems and a local government agency focused on caring for poor patients was supposed to be mutually beneficial for everyone involved. But it didn’t quite turn out that way. The alliance in theory meant that Travis County, home to the growing metro area of Austin, could provide more care to low-income patients cheaper than other big cities in the state.

Medical Schools 259

Medical Schools Hospitals 259

Pharmaceutical Commerce

JANUARY 2, 2024

Agreement includes novel cell therapy for hematology that has the opportunity to bring a potential best-in-class treatment to patients with blood cancers.

105

105

STAT

JANUARY 2, 2024

Is it too early to say that the health tech boom feels like a million years ago? In 2020 and 2021, the jolt of pandemic and favorable economic conditions created an explosion of adoption and investment for companies that hoped to transform some corner of the stodgy health care system with technology. Those roaring days feel like a distant memory. Many of those would-be disrupters are now struggling through a much different environment.

241

241

European Pharmaceutical Review

JANUARY 2, 2024

A paper published in the European Journal of Pharmaceutics and Biopharmaceutics has reviewed the current application status of Quality by Design (QbD) within the framework of the ICH guidelines (ICH Q8(R2) – Q14 and ICH Q2(R2)). Over the past several years, the pharmaceutical industry has faced challenges regarding quality assurance in drug development, the author asserted.

Drug Development 97

Drug Development Biosimilars Documentation 97

STAT

JANUARY 2, 2024

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: In December, Vertex Pharmaceuticals announced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.

Diabetes 223

Diabetes 223

PharmaTech

JANUARY 2, 2024

Reviewing regulatory documents, such as 483 forms and Warning Letters, can aid in determining a facility’s inspection readiness, says Siegfried Schmitt, vice president, Technical at Parexel.

Documentation 92

Documentation 92

STAT

JANUARY 2, 2024

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter  following the flow of money in medicine.  Sign up  to get it in your inbox every Monday.  UnitedHealth had rules to deny rehab care for certain MA members Throughout 2023, my colleague Casey Ross and I explored how UnitedHealth Group and its care management subsidiary, NaviHealth, have used an algorithm to cut off rehab care for people enrolled in Medicare Advantage.

Medical Schools 202

Medical Schools Hospitals 202

Express Pharma

JANUARY 2, 2024

BDR Pharmaceuticals has introduced BDENZA, an oral solution in 32mg/mL for the management of prostate cancer. BDENZA will be available at Rs 27,000 for 150mL. The company informed that the formulation offers lesser side effects in comparison to existing oral dosage forms of Enzalutamide. Dr Aravind Badiger, Director, Technical Formulation, “Changing how we treat prostate cancer, BDENZA ORAL SOLUTION brings a mix of benefits to make things better for patients.

Dosage 93

Dosage 93

STAT

JANUARY 2, 2024

CAMBRIDGE — Vietnamese-born entrepreneur Jean Pham is “graduating” from LabCentral, a biotech launchpad on the edge of Kendall Square, after enjoying free lab space for the past year. Pham and a pair of employees at her three-year-old company, Cellens, shared high-tech research instruments with scores of other scientists, under a LabCentral program aiding startups owned by women and people of color.

Drug Development 191

Drug Development 191

Express Pharma

JANUARY 2, 2024

Glenmark Pharmaceuticals has launched a biosimilar of anti-diabetic drug, Liraglutide, in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI). It is priced at around Rs 100 for a standard dose of 1.2 mg (per day). Liraglutide belongs to the class of glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs, which increase glucose-dependent insulin secretion and decrease in appropriate glucagon secretion.

Diabetes 90

Diabetes Biosimilars 90

Outsourcing Pharma

JANUARY 2, 2024

A Los Angeles clinic is holding a free webinar covering the facts and myths about ketamine following the death of late actor, Matthew Perry.

100

100

Welltopia Pharmacy

JANUARY 2, 2024

Explore 'What is LDN good for?' Learn how it effectively manages chronic pain, inflammation, and various autoimmune disorders in this comprehensive guide.

Compounding 91

Compounding 91

The Pharmacist

JANUARY 2, 2024

The chief pharmaceutical officer (CPhO) for England has warned that pharmacy teams will experience challenging circumstances over the coming weeks and months, due to high demand, staff shortages, sickness and industrial action. But in a joint letter with the General Pharmaceutical Council (GPhC) published today, CPhO David Webb and GPhC chief executive Duncan Rudkin sought […] The post CPhO warns of ‘significant’ and ‘prolonged’ pressures appeared first on The Pharmacist.

80

80

pharmaphorum

JANUARY 2, 2024

Novo Nordisk is planning to open an AI research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations

89

89

Express Pharma

JANUARY 2, 2024

On December 6, India’s Central Drugs Standard Control Organisation (CDSCO) issued a letter asking state and union territory regulators to defer the proposed risk based inspections of manufacturing units and private testing labs scheduled between December 11-22, to focus on verifying the supply chain and quality of propylene glycol (PG), a key ingredient in cough syrups.

86

86

pharmaphorum

JANUARY 2, 2024

Astellas has licensed up to four macrophage enhancer drugs with potential as cancer immunotherapies from Elpiscience in a $1.

102

102

Pharma Times

JANUARY 2, 2024

The programme is the only remote, digital delivery nursing home training programme for dementia

Nursing Homes 108

Nursing Homes 108

European Pharmaceutical Review

JANUARY 2, 2024

For an upfront price of $1.0 billion, AstraZeneca has agreed to acquire Gracell Biotechnologies, supporting the development of cell therapies in haematology and autoimmune diseases. Gracell’s FasTCAR-enabled B-cell maturation antigen (BCMA)/CD19 dual-targeting autologous CAR-T cell therapy GC012F, is an asset AstraZeneca will gain access to as part of the new acquisition agreement announced on 26 December 2023.

Immunity 81

Immunity Immunization 81

Outsourcing Pharma

JANUARY 2, 2024

The US Food and Drink Administration (FDA) has approved Calliditas Therapeutics' Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with IgAN.

81

81

PharmExec

JANUARY 2, 2024

Merger agreement includes the Gracell FasTCAR platform, which could significantly improve the efficacy of CAR T-cell therapies.

98

98

European Pharmaceutical Review

JANUARY 2, 2024

According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drug pricing pressures. Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024. Inflation and geopolitical pressure The second biggest negative impact was thought to be geopolitical conflicts and inflation.

Drug Pricing 80

Drug Pricing Drug Development 80

Outsourcing Pharma

JANUARY 2, 2024

Bristol Myers Squibb has announced it has acquired Karuna Therapeutics, Inc., for a total equity value of $14 billion or $12.7 billion net of estimated cash acquired.

81

81

pharmaphorum

JANUARY 2, 2024

Shares in US biotech Anavex Life Sciences fell sharply this morning after Rett syndrome candidate Anavex 2-73 failed a phase 2/3 trial

91

91

Pharma Times

JANUARY 2, 2024

The number of people getting tested over the last decade has increased by 133%

108

108